R&D News | pharmaphorum

News

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

News

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Data readout puts J&J's bladder cancer drug back on track

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

News

Sky Labs' smart ring tops Apple Watch in AFib comparison

A smart ring developed by South Korean healthtech Sky Labs has outperformed the Apple Watch in a head-to-head comparison.

News

Roche joins the pharma firms planning big US investments

Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.

AstraZeneca joins Tempus, Pathos in cancer AI project

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Has trial result burst BMS' Cobenfy bubble?

Data readout puts J&J's bladder cancer drug back on track

Sky Labs' smart ring tops Apple Watch in AFib comparison

Roche joins the pharma firms planning big US investments

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks